Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on March 8, 2018. The filing serves as a Regulation FD disclosure regarding a significant corporate event rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on a regulatory milestone and does not contain financial statement data.
Material Changes
The primary material event reported is the acceptance of the New Drug Application (NDA) for TX-001HR by the U.S. Food and Drug Administration (FDA). TX-001HR is an investigational bio-identical hormone therapy combining estradiol and progesterone in a single oral softgel, intended for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
Guidance, Outlook, and Risks
The filing confirms the establishment of a Prescription Drug User Fee Act (PDUFA) date for the NDA review, though the specific date is not detailed in the text provided. The document includes standard disclaimers stating that the information furnished in Items 7.01 and 9.01 is not deemed "filed" under Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific PDUFA decision date for the TX-001HR NDA in the referenced press release (Exhibit 99.1).
- Review the full text of the press release for details on the FDA's review timeline and potential approval scenarios.
- Confirm the current development status and clinical trial data supporting the TX-001HR application.
- Check subsequent filings for any updates on the FDA's final decision regarding the NDA.